Rani Therapeutics Holdings, Inc.

NasdaqGM:RANI Stock Report

Market Cap: US$31.8m

Rani Therapeutics Holdings Valuation

Is RANI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RANI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RANI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RANI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RANI?

Key metric: As RANI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RANI. This is calculated by dividing RANI's market cap by their current revenue.
What is RANI's PS Ratio?
PS Ratio14.4x
SalesUS$1.20m
Market CapUS$31.76m

Price to Sales Ratio vs Peers

How does RANI's PS Ratio compare to its peers?

The above table shows the PS ratio for RANI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.1x
AYTU Aytu BioPharma
0.2x13.96%US$18.9m
LYRA Lyra Therapeutics
12.1x57.19%US$14.6m
MRMD MariMed
0.2x7.25%US$27.4m
CBST.F Cannabist Company Holdings
0.06x-14.57%US$23.7m
RANI Rani Therapeutics Holdings
14.4x66.77%US$31.8m

Price-To-Sales vs Peers: RANI is expensive based on its Price-To-Sales Ratio (14.4x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does RANI's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

61 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
0.7x0.42%US$10.57b
PRGO Perrigo
0.8x2.25%US$3.65b
OGN Organon
0.4x1.43%US$2.56b
AMRX Amneal Pharmaceuticals
0.9x7.87%US$2.55b
RANI 14.4xIndustry Avg. 4.7xNo. of Companies61PS048121620+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RANI is expensive based on its Price-To-Sales Ratio (14.4x) compared to the US Pharmaceuticals industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is RANI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RANI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.4x
Fair PS Ratio19x

Price-To-Sales vs Fair Ratio: RANI is good value based on its Price-To-Sales Ratio (14.4x) compared to the estimated Fair Price-To-Sales Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RANI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.51
US$7.80
+1,417.81%
37.51%US$12.00US$4.00n/a5
Jun ’26US$0.56
US$7.80
+1,294.85%
37.51%US$12.00US$4.00n/a5
May ’26US$1.07
US$9.50
+787.85%
30.23%US$14.00US$5.00n/a6
Apr ’26US$1.23
US$11.57
+840.77%
23.03%US$15.00US$8.00n/a7
Mar ’26US$1.53
US$11.50
+651.63%
28.51%US$17.00US$8.00n/a8
Feb ’26US$1.39
US$11.50
+727.34%
28.51%US$17.00US$8.00n/a8
Jan ’26US$1.37
US$11.50
+739.42%
28.51%US$17.00US$8.00n/a8
Dec ’25US$2.02
US$11.50
+469.31%
28.51%US$17.00US$8.00n/a8
Nov ’25US$2.31
US$11.75
+408.66%
26.15%US$17.00US$8.00n/a8
Oct ’25US$2.31
US$11.75
+408.66%
26.15%US$17.00US$8.00n/a8
Sep ’25US$3.20
US$11.75
+267.19%
26.15%US$17.00US$8.00n/a8
Aug ’25US$2.72
US$12.25
+350.37%
23.71%US$17.00US$8.00n/a8
Jul ’25US$3.82
US$11.13
+191.23%
23.11%US$15.00US$8.00US$0.518
Jun ’25US$5.50
US$10.57
+92.21%
21.37%US$14.00US$8.00US$0.567
May ’25US$6.37
US$8.86
+39.04%
29.83%US$12.00US$4.00US$1.077
Apr ’25US$3.13
US$8.86
+182.98%
29.83%US$12.00US$4.00US$1.237
Mar ’25US$3.69
US$11.86
+221.33%
48.43%US$21.00US$4.00US$1.537
Feb ’25US$3.45
US$11.86
+243.69%
48.43%US$21.00US$4.00US$1.397
Jan ’25US$3.32
US$11.86
+257.14%
48.43%US$21.00US$4.00US$1.377
Dec ’24US$2.44
US$11.86
+385.95%
48.43%US$21.00US$4.00US$2.027
Nov ’24US$1.91
US$20.50
+973.30%
31.23%US$32.00US$10.00US$2.318
Oct ’24US$2.18
US$22.25
+922.99%
22.78%US$32.00US$15.00US$2.318
Sep ’24US$3.80
US$22.25
+485.53%
22.78%US$32.00US$15.00US$3.208
Aug ’24US$4.32
US$22.75
+426.62%
20.94%US$32.00US$15.00US$2.728
Jul ’24US$4.12
US$22.75
+452.18%
20.94%US$32.00US$15.00US$3.828
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
US$7.80
Fair Value
93.4% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 00:25
End of Day Share Price 2025/06/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rani Therapeutics Holdings, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Edward NashCanaccord Genuity
Mitchell KapoorH.C. Wainwright & Co.